Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Lynparza and Talzenna are targeted therapies known as PARP inhibitors. Both agents have received FDA approval for treating metastatic breast cancer caused by a BRCA mutation. BRACAnalysis CDx—a companion diagnostic test—received approval at the same time as the agents. The National Comprehensive Cancer Network (NCCN) has added
Lynparza as a preferred single agent treatment for people with advanced breast cancer and a BRCA mutation.
Research is now also looking at
PARP inhibitor effectiveness in additional settings including:
You can look for research studies enrolling patients with breast cancer by visiting FORCE's Research Study Search Tool.